Regions
MAIN/REGIONS
regions/
Regions
  1. Americas
  2. Asia & Oceania
  3. Europe
  4. Middle East & Africa
  1. Solutions
  2. Products
  3. Insights
  4. About
  5. Careers
  6. Contact Us
MAIN/search
MAIN/Solutions
Solutions/
SOLUTIONS
  • Research & Development
  • Real World Evidence
  • Commercialization
  • Safety & Regulatory Compliance
  • Technologies
LIFE SCIENCE SEGMENTS
HEALTHCARE SEGMENTS
THERAPEUTIC AREAS

Impacting People's Lives

"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.

LEARN MORE
Harness the power to transform clinical development

Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.

Research & Development Overview
Research & Development Quick Links
Real World Evidence. Real Confidence. Real Results.

Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.

REAL WORLD EVIDENCE OVERVIEW
Real World Evidence Quick Links
See markets more clearly. Opportunities more often.

Elevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.

COMMERCIALIZATION OVERVIEW
Commercialization Quick Links
Service driven. Tech-enabled. Integrated compliance.

Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.

COMPLIANCE OVERVIEW
Safety & Regulatory Compliance Quick Links
Intelligence that transforms life sciences end-to-end.

When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.

TECHNOLOGIES OVERVIEW
Technology Quick Links
MAIN/Products
Products/
CLINICAL PRODUCTS
COMMERCIAL PRODUCTS
COMPLIANCE, SAFETY, REG PRODUCTS
REAL WORLD PRODUCTS

CASE STUDY

"Data in a Day

LEARN MORE
MAIN/Insights
Insights/
BLOGS, WHITE PAPERS & CASE STUDIES

Explore our library of insights, thought leadership, and the latest topics & trends in healthcare.

DISCOVER INSIGHTS
THE IQVIA INSTITUTE

An in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.

SEE LATEST REPORTS

INSTITUTE REPORT

"Digital Health Trends 2024 - Implications for Research and Patient Care

READ MORE

EMEA Insights

"IQVIA thought leadership with a focus on EMEA.

Learn more

WHITE PAPER

"DCTs Deliver Big ROI

LEARN MORE

WHITE PAPER

"Capturing value at scale: The $4 billion RWE imperative

LEARN MORE
MAIN/About
About/
FEATURED INNOVATIONS
  • IQVIA Connected Intelligence™
  • IQVIA Healthcare-grade AI™
  • Human Data Science Cloud
  • IQVIA Innovation Hub
  • Decentralized Trials
  • Patient Experience Solutions with Apple devices
WHO WE ARE
NEWS & RESOURCES

INVESTOR RELATIONS

"Visit our investor relations site for more information.

LEARN MORE
Unlock your potential to drive healthcare forward

By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.

LEARN MORE
IQVIA AI is Healthcare-grade AI

Building on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.

LEARN MORE

Your healthcare data deserves more than just a cloud.

The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.

LEARN MORE
Innovations make an impact when bold ideas meet powerful partnerships

The IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.

LEARN MORE
Proven, faster DCT solutions

IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.

LEARN MORE
IQVIA Patient Experience Solutions with Apple devices

Empowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm.

LEARN MORE
MAIN/Careers
Careers/
WORKING AT IQVIA

Our mission is to accelerate innovation for a healthier world. Together, we can solve customer challenges and improve patient lives.

LEARN MORE
LIFE AT IQVIA

Careers, culture and everything in between. Find out what’s going on right here, right now.

LEARN MORE

WE’RE HIRING

"Improving human health requires brave thinkers who are willing to explore new ideas and build on successes. Unleash your potential with us.

SEARCH JOBS
MAIN/Contact Us
Contact Us/
Blog
Inventing an Asian Genomic Future
Jude Uzonwanne, Principal, Consulting Services, Asia Pacific
Jun 25, 2018
  • Blogs
  • Inventing an Asian Genomic Future

Who will win Asia’s precision medicine race?  Who will be able to wring the greatest value from healthcare spending on aging populations (e.g. China, Japan) and to treat soaring rates of chronic disease (e.g. diabetes, cardiovascular disease.) Who will be able to improve the first-line treatment response rates? Who will improve overall population wellness by incentivizing healthy behaviors? 

No matter who wins, all in the race will rely on a key intermediary: genetic testing companies. 

Today, Asia’s genetics testing market is worth about USD$1.3 billion (2017). It’s expected to reach ~$4 billion by 2023, according to BBC Research. If adoption rates for personal genetics information increase and regulations ease that 2023 number may be low. 

The Asia market can be examined through several lenses. One is by end-use segments, i.e. direct-to-consumer testing; treatment related testing; and research testing. For most investors, the DTC and TRT segments present the most interesting opportunities. 

In the DTC segment, market leaders include Prenetics and Asia Genomics: they are the region’s equivalents to 23andme in the United States. The TRT segment is by far the largest addressable genetic testing market at ~70 percent of revenues. This segment includes China’s BGI, Foundation Medicine and Illumina. The TRT segment is expected to grow rapidly as companion diagnostics increasingly becomes a standard part of drug treatments.  We are also starting to see TRT and DTC companies push into each other’s markets to protect growth – even though the majority of Asia remains unserved. 

Another lens is a value chain view.  This divides the market into upstream, midstream and downstream (where the end-use segments, e.g. DTC, operate). Upstream equipment developer and consumables providers (e.g. reagents) and midstream data services also represent attractive plays. As innovation grows, the cost of equipment from the likes of ThermoFisher, Helicos and new entrants is likely to continue to fall, creating a virtuous cycle. 

Another intriguing play is the emerging data-services segment currently served by players such as Qiagen, SevenBridges and Bina. Data analytics and security around libraries of DNA embedded in patient electronic records may become the most important electronic assets –perhaps even more than financial assets. Data security is of the utmost importance.  Hence it is likely that a disruptive storage, encryption and sharing platforms will emerge to address this need. Innovations using a combination of technologies e.g. biophysics and blockchain will spawn a range of start-ups over the next three years to solve for this issue.

Recognizing the potential for jobs, initial public offerings, and tax revenues, governments are thinking about how best to support the emergence of a genomic cluster and its related businesses. These measures include reviewing regulatory provisions around privacy, building a publicly financed library of genetic data, integrating genetic data with population health data, and supporting the growth of specialized talent, e.g. biostatisticians.

Many of these efforts are at pilot stage. South Korea recently began a program to create a library of its citizens genetic maps. Such de-identified data, if made accessible to biopharmaceutical and devices companies, would allow the creation of more drugs targeted to treat patients with shared genetic traits.  IQVIA has developed a strategic framework required to align private investors and public good to create a productive genomics industry cluster.

Investors are in the early wave of opportunity.  Start-ups and more established players offer investors an opportunity to win by improving therapy targeting, reducing the cost to treat, and leveraging data in profound new applications. 

The most attractive companies for investment are those that engage closely with their host jurisdictions to unlock the potential of genomics while protecting privacy and patient decision-rights over their health data. 

Contributors:

  • Michele Valente
    Consultant, Asia Pacific
  • Yu Xiang
    Analyst, Asia Pacific
Contact Us